Details for Patent: 6,916,784
✉ Email this page to a colleague
Title: | Cyclic peptide antifungal agents and process for preparation thereof |
Abstract: | Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R adn R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R.dbd.H) forms of the compounds. |
Inventor(s): | Burkhardt; Frederick J. (Indianapolis, IN), Debono; Manuel (Indianapolis, IN), Nissen; Jeffrey S. (Indianapolis, IN), Turner, Jr.; William W. (Bloomington, IN) |
Assignee: | Eli Lilly and Company (Indianapolis, IN) |
Filing Date: | Feb 27, 2003 |
Application Number: | 10/378,004 |
Claims: | 1. A compound represented by the formula ##STR237## wherein R is --O(CH.sub.2).sub.3 CH.sub.3, --O(CH.sub.2).sub.4 CH.sub.3, --O(CH.sub.2).sub.5 CH.sub.3, --O(CH.sub.2).sub.2 O(CH.sub.2).sub.3 CH.sub.3, or --O(CH.sub.2).sub.2 OC(CH.sub.3).sub.3. 2. A pharmaceutically acceptable salt of a compound according to claim 1. 3. A pharmaceutical formulation comprising a compound represented by the formula ##STR238## wherein R is --O(CH.sub.2).sub.3 CH.sub.3, --O(CH.sub.2).sub.4 CH.sub.3, --O(CH.sub.2).sub.5 CH.sub.3, --O(CH.sub.2).sub.2 O(CH.sub.2).sub.3 CH.sub.3, or --O(CH.sub.2).sub.2 OC(CH.sub.3).sub.3 and a pharmaceutically acceptable carrier. 4. A pharmaceutical formulation comprising a pharmaceutically acceptable salt of the formulation according to claim 3. 5. A method for inhibiting parasitic activity comprising contacting a formulation of claim 3 with a parasite. 6. A method of inhibiting fungal activity comprising contacting a formulation of claim 3 with a fungus. 7. A method of inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a formulation of claim 3 to said individual. 8. A method of inhibiting the growth of Pneumocystis carinii comprising contacting a formulation of claim 3 with Pneumocystis carinii. 9. A pharmaceutical formulation comprising a compound having the following formula: ##STR239## and a pharmaceutically acceptable carrier, wherein the formulation is formulated for topical administration. 10. The pharmaceutical formulation of claim 9, wherein the pharmaceutically acceptable carrier comprises a dry powder or a solubilizing liquid. 11. The pharmaceutical formulation of claim 10, wherein the solubilizing liquid is aqueous. 12. The pharmaceutical formulation of claim 10, wherein the solubilizing liquid is non-aqueous. 13. The pharmaceutical formulation of claim 12, wherein the non-aqueous solubilizing liquid is an alcohol or glycol. 14. A method of inhibiting fungal activity comprising contacting a formulation of claim 9, with a fungus via topical administration. |